FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012940838> ?p ?o ?g. }

• W2012940838 endingPage "2314" @default.
• W2012940838 startingPage "2303" @default.
• W2012940838 abstract "We report the results of a phase III open-label, randomized, multicenter trial comparing tacrolimus/methotrexate to cyclosporine/methotrexate for graft-versus-host disease (GVHD) prophylaxis after HLA-identical sibling marrow transplantation in patients with hematologic malignancy. The primary objective of this study was to compare the incidence of moderate to severe (grade II-IV) acute GVHD. Secondary objectives were to compare the relapse rate, disease-free survival, overall survival, and the incidence of chronic GVHD. Patients were stratified according to age ( /=40) and for male recipients of a marrow graft from an alloimmunized female. There was a significantly greater proportion of patients with advanced disease randomized to tacrolimus arm (P = . 02). The incidence of grade II-IV acute GVHD was significantly lower in patients who received tacrolimus than patients in the cyclosporine group (31.9% and 44.4%, respectively; P = .01). The incidence of grade III-IV acute GVHD was similar, 17.1% in cyclosporine group and 13.3% in the tacrolimus group. There was no difference in the incidence of chronic GVHD between the tacrolimus and the cyclosporine group (55.9% and 49.4%, respectively; P = .8). However, there was a significantly higher proportion of patients in the cyclosporine group who had clinical extensive chronic GVHD (P = . 03). The relapse rates of the two groups were similar. The patients in the cyclosporine arm had a significantly better 2-year disease-free survival and overall survival than patients in the tacrolimus arm, 50.4% versus 40.5% (P = .01) and 57.2% versus 46.9% (P = .02), respectively. The significant difference in the overall and disease-free survival was largely the result of the patients with advanced disease, 24.8% with tacrolimus versus 41.7% with cyclosporine (P = .006) and 20.4% with tacrolimus versus 28% with cyclosporine (P = .007), respectively. There was a higher frequency of deaths from regimen-related toxicity in patients with advanced disease who received tacrolimus. There was no difference in the disease-free and overall survival in patients with nonadvanced disease. These results show the superiority of tacrolimus/methotrexate over cyclosporine/methotrexate in the prevention of grade II-IV acute GVHD with no difference in disease-free or overall survival in patients with nonadvanced disease. The survival disadvantage in advanced disease patients receiving tacrolimus warrants further investigation." @default.
• W2012940838 created "2016-06-24" @default.
• W2012940838 creator A5001898266 @default.
• W2012940838 creator A5005086749 @default.
• W2012940838 creator A5007847102 @default.
• W2012940838 creator A5012108142 @default.
• W2012940838 creator A5016399826 @default.
• W2012940838 creator A5023798810 @default.
• W2012940838 creator A5029681457 @default.
• W2012940838 creator A5029953583 @default.
• W2012940838 creator A5033263164 @default.
• W2012940838 creator A5033267787 @default.
• W2012940838 creator A5041249662 @default.
• W2012940838 creator A5047337391 @default.
• W2012940838 creator A5049554397 @default.
• W2012940838 creator A5054037976 @default.
• W2012940838 creator A5057948361 @default.
• W2012940838 creator A5064617830 @default.
• W2012940838 creator A5065409070 @default.
• W2012940838 creator A5066528744 @default.
• W2012940838 creator A5066741737 @default.
• W2012940838 creator A5068615382 @default.
• W2012940838 creator A5069014112 @default.
• W2012940838 creator A5085360755 @default.
• W2012940838 creator A5085787488 @default.
• W2012940838 date "1998-10-01" @default.
• W2012940838 modified "2023-10-17" @default.
• W2012940838 title "Phase III Study Comparing Methotrexate and Tacrolimus (Prograf, FK506) With Methotrexate and Cyclosporine for Graft-Versus-Host Disease Prophylaxis After HLA-Identical Sibling Bone Marrow Transplantation" @default.
• W2012940838 cites W128488591 @default.
• W2012940838 cites W147854875 @default.
• W2012940838 cites W1491993932 @default.
• W2012940838 cites W1500757144 @default.
• W2012940838 cites W1510827637 @default.
• W2012940838 cites W1562876511 @default.
• W2012940838 cites W1599864954 @default.
• W2012940838 cites W165753144 @default.
• W2012940838 cites W1845765288 @default.
• W2012940838 cites W1868440535 @default.
• W2012940838 cites W1934171667 @default.
• W2012940838 cites W1969275068 @default.
• W2012940838 cites W1977536924 @default.
• W2012940838 cites W1979300931 @default.
• W2012940838 cites W1991688431 @default.
• W2012940838 cites W2000191478 @default.
• W2012940838 cites W2006204311 @default.
• W2012940838 cites W205753852 @default.
• W2012940838 cites W2076671804 @default.
• W2012940838 cites W2086678484 @default.
• W2012940838 cites W2089532890 @default.
• W2012940838 cites W2093717575 @default.
• W2012940838 cites W2094292853 @default.
• W2012940838 cites W2099613288 @default.
• W2012940838 cites W2101934730 @default.
• W2012940838 cites W2149210939 @default.
• W2012940838 cites W215523164 @default.
• W2012940838 cites W2222053506 @default.
• W2012940838 cites W2261015395 @default.
• W2012940838 cites W2288134438 @default.
• W2012940838 cites W2312610590 @default.
• W2012940838 cites W2337969406 @default.
• W2012940838 cites W2397761189 @default.
• W2012940838 cites W2398341633 @default.
• W2012940838 cites W2410704717 @default.
• W2012940838 cites W2411434130 @default.
• W2012940838 cites W2411862517 @default.
• W2012940838 cites W2412193650 @default.
• W2012940838 cites W2416853657 @default.
• W2012940838 cites W2418611715 @default.
• W2012940838 cites W2436291617 @default.
• W2012940838 cites W2471971207 @default.
• W2012940838 cites W297517734 @default.
• W2012940838 cites W303912468 @default.
• W2012940838 cites W304838697 @default.
• W2012940838 cites W307132063 @default.
• W2012940838 cites W315558393 @default.
• W2012940838 cites W95208818 @default.
• W2012940838 cites W2980822521 @default.
• W2012940838 cites W2995133996 @default.
• W2012940838 doi "https://doi.org/10.1182/blood.v92.7.2303" @default.
• W2012940838 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9746768" @default.
• W2012940838 hasPublicationYear "1998" @default.
• W2012940838 type Work @default.
• W2012940838 sameAs 2012940838 @default.
• W2012940838 citedByCount "146" @default.
• W2012940838 countsByYear W20129408382012 @default.
• W2012940838 countsByYear W20129408382013 @default.
• W2012940838 countsByYear W20129408382014 @default.
• W2012940838 countsByYear W20129408382015 @default.
• W2012940838 countsByYear W20129408382016 @default.
• W2012940838 countsByYear W20129408382017 @default.
• W2012940838 countsByYear W20129408382018 @default.
• W2012940838 countsByYear W20129408382019 @default.
• W2012940838 countsByYear W20129408382020 @default.
• W2012940838 countsByYear W20129408382021 @default.
• W2012940838 countsByYear W20129408382022 @default.
• W2012940838 countsByYear W20129408382023 @default.
• W2012940838 crossrefType "journal-article" @default.
• W2012940838 hasAuthorship W2012940838A5001898266 @default.

• next